JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities at a market outperform rating and $3 price target. Weekly Factive prescriptions were 5,555, or 0.85% of the quinolone class of antibiotics. This compares to 5,260 prescriptions in the previous week. Testim prescriptions for the week ended Nov. 11 were 4,898 shares compared with 5,181 shares for the week ended Nov. 4. Shares of the Waltham, Mass., biopharmaceutical company were down 3 cents, or 1.43%, at $2.07 on volume of 603,619 shares versus the three-month running average of 698,200 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.